Santarus Stock Hits New 52-Week High (SNTS)

NEW YORK ( TheStreet) -- Santarus (Nasdaq: SNTS) hit a new 52-week high Friday as it is currently trading at $6.54, above its previous 52-week high of $6.50 with 329,808 shares traded as of 12:35 p.m. ET. Average volume has been 397,500 shares over the past 30 days.

Santarus has a market cap of $394.4 million and is part of the health care sector and drugs industry. Shares are up 95.2% year to date as of the close of trading on Thursday.

Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company has a P/E ratio of 70, below the average drugs industry P/E ratio of 90 and above the S&P 500 P/E ratio of 17.7.

• Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Santarus as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Santarus Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.